Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France

Chouaïd, C.; Bensimon, L.; Clay, E.; Millier, A.; Lévy-Bachelot, L.; Huang, Min; Lévy, Pierre

doi:10.1016/j.lungcan.2018.11.008

Public

Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France

Published in Lung Cancer • Nov 23, 2018

Authors:

C. Chouaïd

L. Bensimon

E. Clay

Abstract

INTRODUCTION: In the KEYNOTE-024 trial, pembrolizumab demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) versus Standard-of-Care (SoC) platinum-based doublets for first-line treatment of PD-L1 -positive (≥50%) metastatic Non-Small-Cell Lung Cancer (NSC...

Subject

Pembrolizumab

Medicine

Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!